AU2017261292B2 - DNA monoclonal antibodies targeting IL-6 and CD126 - Google Patents

DNA monoclonal antibodies targeting IL-6 and CD126 Download PDF

Info

Publication number
AU2017261292B2
AU2017261292B2 AU2017261292A AU2017261292A AU2017261292B2 AU 2017261292 B2 AU2017261292 B2 AU 2017261292B2 AU 2017261292 A AU2017261292 A AU 2017261292A AU 2017261292 A AU2017261292 A AU 2017261292A AU 2017261292 B2 AU2017261292 B2 AU 2017261292B2
Authority
AU
Australia
Prior art keywords
ser
val
leu
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017261292A
Other languages
English (en)
Other versions
AU2017261292A1 (en
Inventor
David Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Wistar Institute of Anatomy and Biology
Original Assignee
University of Pennsylvania Penn
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, Wistar Institute of Anatomy and Biology filed Critical University of Pennsylvania Penn
Publication of AU2017261292A1 publication Critical patent/AU2017261292A1/en
Priority to AU2024203109A priority Critical patent/AU2024203109A1/en
Application granted granted Critical
Publication of AU2017261292B2 publication Critical patent/AU2017261292B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017261292A 2016-05-05 2017-05-05 DNA monoclonal antibodies targeting IL-6 and CD126 Active AU2017261292B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203109A AU2024203109A1 (en) 2016-05-05 2024-05-10 DNA monoclonal antibodies targeting IL-6 and CD126

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332377P 2016-05-05 2016-05-05
US62/332,377 2016-05-05
PCT/US2017/031193 WO2017192933A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203109A Division AU2024203109A1 (en) 2016-05-05 2024-05-10 DNA monoclonal antibodies targeting IL-6 and CD126

Publications (2)

Publication Number Publication Date
AU2017261292A1 AU2017261292A1 (en) 2018-12-20
AU2017261292B2 true AU2017261292B2 (en) 2024-06-06

Family

ID=60203626

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017261292A Active AU2017261292B2 (en) 2016-05-05 2017-05-05 DNA monoclonal antibodies targeting IL-6 and CD126
AU2024203109A Pending AU2024203109A1 (en) 2016-05-05 2024-05-10 DNA monoclonal antibodies targeting IL-6 and CD126

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203109A Pending AU2024203109A1 (en) 2016-05-05 2024-05-10 DNA monoclonal antibodies targeting IL-6 and CD126

Country Status (12)

Country Link
US (1) US20190192692A1 (enExample)
EP (1) EP3452106A4 (enExample)
JP (3) JP7311113B2 (enExample)
KR (3) KR20190031439A (enExample)
CN (1) CN109789224A (enExample)
AU (2) AU2017261292B2 (enExample)
BR (1) BR112018072697A2 (enExample)
CA (1) CA3023089A1 (enExample)
EA (1) EA201892524A1 (enExample)
MX (2) MX2018013523A (enExample)
SG (2) SG11201809786TA (enExample)
WO (1) WO2017192933A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167584B (zh) * 2016-11-07 2024-06-07 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体
KR102635888B1 (ko) 2019-03-19 2024-02-15 엘지전자 주식회사 공기청정기
WO2022155404A1 (en) * 2021-01-14 2022-07-21 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093894A2 (en) * 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1562968T3 (da) * 2001-11-14 2013-10-28 Janssen Biotech Inc Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
DK1960430T3 (da) * 2005-12-09 2015-01-05 Ucb Pharma Sa Antistofmolekyler der har specificitet for humant il-6
AU2007282023B2 (en) * 2006-08-03 2012-09-13 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
US8034344B2 (en) * 2008-05-13 2011-10-11 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
CA2818813C (en) * 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093894A2 (en) * 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same

Also Published As

Publication number Publication date
AU2017261292A1 (en) 2018-12-20
SG10202011023YA (en) 2020-12-30
KR20250011241A (ko) 2025-01-21
JP7311113B2 (ja) 2023-07-19
AU2024203109A1 (en) 2024-05-30
EP3452106A1 (en) 2019-03-13
WO2017192933A1 (en) 2017-11-09
CN109789224A (zh) 2019-05-21
KR20230058733A (ko) 2023-05-03
JP2025147175A (ja) 2025-10-06
CA3023089A1 (en) 2017-11-09
EA201892524A1 (ru) 2019-04-30
KR20190031439A (ko) 2019-03-26
BR112018072697A2 (pt) 2019-02-19
MX2018013523A (es) 2019-06-10
SG11201809786TA (en) 2018-12-28
EP3452106A4 (en) 2020-01-08
JP2019518074A (ja) 2019-06-27
MX2025009846A (es) 2025-09-02
US20190192692A1 (en) 2019-06-27
JP2023086734A (ja) 2023-06-22

Similar Documents

Publication Publication Date Title
KR20170087486A (ko) 일반 경쇄 및 이의 사용 방법
AU2017261374B2 (en) DNA antibody constructs for use against pseudomonas aeruginosa
AU2017276726B2 (en) Herpesvirus with modified glycoprotein D
AU2024203109A1 (en) DNA monoclonal antibodies targeting IL-6 and CD126
AU2022219332A1 (en) Anti-cd112r antibody and use thereof
KR20220117915A (ko) 항-muc1 조성물 및 사용 방법
KR20230125851A (ko) 인플루엔자 바이러스를 표적으로 하는 dna 단일 클론항체
US20240376179A1 (en) Dna antibody constructs for use against middle east respiratory syndrome coronavirus
JP2023126321A (ja) ライム病に対する使用のためのｄｎａ抗体構築物
US20240287166A1 (en) Dna antibody constructs for use against plasmodium parasites
US20230340082A1 (en) Dna antibody constructs for use against rotavirus
RU2813829C2 (ru) Конструкции днк-антител для применения против болезни лайма
HK40009046A (en) Dna monoclonal antibodies targeting il-6 and cd126
HK40013455A (en) Dna antibody constructs for use against lyme disease
WO2019152607A1 (en) Nucleic acid antibody constructs for use against ebola virus
EA042308B1 (ru) Днк-моноклональные антитела, нацеленные на il-6
WO2019152602A1 (en) Structurally modified flavivirus dmabs
KR20190114963A (ko) 에볼라 바이러스에 대한 사용을 위한 dna 항체 작제물
HK40009043A (zh) 靶向检查点分子的dna单克隆抗体
HK40009739A (en) Dna antibody constructs and method of using same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)